All around the world, millions of people experience reduced quality of life due to allergy. In Europe and the USA alone, more than 80 million people suffer from grass pollen allergy. ALK-Abelló’s allergy vaccines treat not only the symptoms of allergy but also the underlying disease – and at the same time prevent asthma.

ALK-Abelló is a fast-growing company working with the very latest technology in research, development and production. It is the market leader in allergy vaccination in Europe and also commands strong positions in the USA and China. The company has approximately 1,200 employees.